PT  - JOURNAL ARTICLE
AU  - Nanca Cebron Lipovec
AU  - Janez Toni
AU  - Petra Svetina Sorli
AU  - Mitja Kosnik
TI  - Drug interaction in tuberculosis treatment - The role of pharmacists
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P2604
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P2604.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P2604.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - IntroductionTuberculosis as a disease demands long-term multidrug treatment. Most first-line antituberculotic drugs have clinically significant interactions with numerous drugs. In our clinic pharmacists review the drug therapy of all patients receiving antituberculotic drugs.AimTo screen for drug interactions in patients with first-line antituberculotic drugs and assess their clinical significance.MethodsFrom June 2011 to February 2012 clinical pharmacists performed regular reviews of interactions with first-line antituberculotic therapy in 57 hospitalized patients. The detected interactions were discussed with the doctor and changes in therapy implemented. Data on detected interactions were collected and analysed.ResultsDrug interactions were identified in 33,3% (18/54) of patients. The average number of drug interactions per patients was 1,4 (25/18). Most interactions (92%, 23/25) were with rifampicin, 8% (2/25) were with isoniazide. The most common interacting drugs were bisoprolol (5/25), esomeprazole and methadone (each 3/25) and clopidogrel and statins (each 2/29). Other interactions were with warfarin, carbamazepin, methyldigoxin, methylprednisolon, citalopram, risperidon, fentanyl, lercadipine, omeprazole and carvedilol (each 1/29).ConclusionEvery third patient receiving first-line antituberculotic therapy is at risk of experiencing an interaction with drugs in chronic therapy. These drugs belong to various different drug groups. Clinical pharmacists can detect these interactions and suggest interventions to assure safe and effective therapy. The actual clinical significance of these interactions is yet to be analysed.The project was supported by a grant of the Health Insurance Institute of Slovenia.